Malin Corporation Plc

Regulatory Filings • Feb 7, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4031P

Malin Corporation PLC

07 February 2019

Malin Corporation plc

("Malin")

Altan files New Drug Application for Acetaminophen solution with US FDA

-     Malin owns approximately 65% of Altan, a Malin revenue-generative Growth Potential Asset -

Dublin-Ireland, 7 February 2019: Malin Corporation plc (Euronext Dublin:MLC), a company investing in highly innovative life sciences companies, is pleased to note that its subsidiary company, Altan Pharma Limited ("Altan"), has submitted a New Drug Application (NDA) for its formulation of acetaminophen (paracetamol) solution for infusion to the US Food and Drug Administration (FDA) which has been accepted for review.

Altan's intravenous solution is an analgesic used for the treatment of pain and reduction of fever; and offers hospitals more choices for non-opioid forms of pain relief. The formulation is uniquely packaged in safe and flexible containers, often preferred by healthcare providers and has sold more than 200 million units in non-US markets to date.

"We believe this non-opioid form of pain-relief represents a significant commercial opportunity in the US market; and has the potential to offer a favourable product and a more economic solution for hospitals, patients and payors" said Darragh Lyons, Chief Business and Financial Officer of Malin.

Malin owns approximately 65% of Altan.

A copy of Altan's press release is available to view here: http://altanpharma.com/altan-pharma-submits-new-drug-application-for-acetaminophen-solution-for-infusion-for-treatment-of-pain-and-reduction-of-fever/ 

ENDS

For further information, please contact:

Malin

Jessica Bergin, Director of Investor Relations & External Reporting

Tel: +353 (0)1 901 5700

investorrelations@malinplc.com

Consilium Strategic Communications (Financial PR)

Mary-Jane Elliott / Jonathan Birt

Tel: +44 (0)20 3709 5700

malin@consilium-comms.com

Powerscourt (Ireland PR)           

Eavan Gannon                                              

Tel: +353 87 236 5973                            

malin@powerscourt-group.com                                                                          

Davy Corporate Finance (Euronext Growth Adviser)

Brian Garrahy / Daragh O'Reilly

Tel: +353 1 679 6363

About Malin Corporation plc

Malin (Euronext Dublin:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on Euronext Growth Dublin. For more information visit www.malinplc.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCUGUUPPUPBGPM